Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,188 JPY | +0.22% | +2.48% | +20.03% |
Apr. 15 | MC Healthcare, Inc. acquired FreeIll Co., Ltd. from ORIX Corporation. | CI |
Apr. 04 | S&P Global Ratings Cuts Orix's Rating, Outlook Remains Stable | MT |
Strengths
- With a P/E ratio at 11.09 for the current year and 9.37 for next year, earnings multiples are highly attractive compared with competitors.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Consumer Lending
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+20.03% | 23.38B | B | ||
-8.14% | 49.88B | C+ | ||
-5.25% | 30.53B | C+ | ||
+63.88% | 29.08B | - | - | |
+16.97% | 17.94B | B | ||
-6.99% | 11.81B | C+ | ||
+21.92% | 11.27B | B- | ||
-20.90% | 8.31B | - | ||
+14.34% | 8.13B | C | ||
+36.65% | 6.39B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 8591 Stock
- Ratings ORIX Corporation